-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The clinical manifestations of lupus nephritis include hematuria, nephrotic proteinuria, and azotemia in the advanced stage of the disease.
diagnosis
GlaxoSmithKline (GSK) today announced that the European Medicines Management Agency (EMA) adopted a positive person with opinions and Drug Committee (CHMP), recommended that Benlysta (belimumab) Joint immune suppression therapy for active lupus nephritis (LN ).
Management Immunity
The CHMP opinion is based on data from the BLISS-LN study.
.
Original source:
Original source:href="" target="_blank" rel="noopener">leave a message here